Anti-P-selectin Antibodies Block PSGL-1 Adhesion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vasoocclusive pain crises in sickle cell disease and inflammatory bowel diseases, such as Crohn's Disease, are largely symptomatic and do not address the underlying cause of the condition, leading to significant morbidity and mortality, with a need for new therapeutic approaches that target P-selectin to inhibit leukocyte and platelet adhesion.
Innovation Solution
Development of function-blocking antibodies that specifically bind to P-selectin, blocking the binding of PSGL-1 and causing dissociation of preformed P-selectin/PSGL-1 complexes, to prevent leukocyte and platelet adhesion in inflammatory and thrombotic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If symptomatic treatments are used for vasoocclusive pain crises and inflammatory bowel diseases, then immediate relief of symptoms can be achieved, but the underlying cause of the condition remains unaddressed, leading to significant morbidity and mortality
Solution Approach 1:
The patent applies preliminary anti-action by developing antibodies that block P-selectin before it can mediate leukocyte and platelet adhesion. The antibodies are designed to prevent the formation of P-selectin/PSGL-1 complexes, thereby stopping the inflammatory and thrombotic processes before they cause tissue damage and vasoocclusion. This proactive approach addresses the underlying cause rather than merely treating symptoms after they manifest.
2Ease of operation
If current symptomatic treatment approaches are continued, then treatment simplicity is maintained, but significant morbidity and mortality persist due to lack of disease modification
Solution Approach 1:
The patent introduces antibodies as intermediary molecules that specifically bind to P-selectin and block its interaction with PSGL-1. These antibodies act as mediators that interfere with the pathogenic adhesion process without requiring complex surgical interventions or lifestyle changes. The therapeutic approach maintains relative simplicity in administration while achieving disease-modifying effects through targeted molecular intervention.
3Object-affected harmful factors
If P-selectin blocking antibodies are developed to inhibit leukocyte and platelet adhesion, then vasoocclusive events and inflammatory responses can be reduced, but new therapeutic agents with unknown safety profiles are introduced
Solution Approach 1:
The patent employs humanized antibodies that replicate the binding specificity of fully human antibodies while utilizing the well-characterized structure and properties of murine antibodies. By copying the essential binding features into a human framework, the therapeutic agents achieve high affinity for human P-selectin while minimizing immunogenicity and improving safety profiles compared to fully non-human antibodies.
4Reliability
If function-blocking antibodies are used to bind P-selectin and block PSGL-1 binding, then leukocyte and platelet adhesion is prevented, but the complexity of developing and characterizing novel antibody therapeutics increases
Solution Approach 1:
The patent develops antibodies with multiple functions: they block P-selectin/PSGL-1 binding, prevent leukocyte rolling and adhesion, inhibit platelet activation, and reduce vasoocclusive events. This multi-functionality allows a single therapeutic agent to address multiple pathogenic mechanisms simultaneously, reducing the need for multiple separate interventions and simplifying the overall therapeutic regimen despite the complexity of antibody development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antibodies effectively reduce vasoocclusive events and inflammatory responses by inhibiting P-selectin-mediated adhesion, offering a potential therapeutic solution for conditions like sickle cell disease and inflammatory bowel diseases by blocking the initiation and propagation of vasoocclusion and inflammation.
Implementation Method 1
function-blocking antibodies that specifically bind to P-selectin, blocking the binding of PSGL-1 and causing dissociation of preformed P-selectin/PSGL-1 complexes
Implementation Method 2
inhibiting P-selectin-mediated adhesion, offering a potential therapeutic solution for conditions like sickle cell disease and inflammatory bowel diseases by blocking the initiation and propagation of vasoocclusion and inflammation
Data Source
AI summary
Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.